The Soldier's Drug is an analytical history of amphetamines — tracing the compound from a Berlin chemistry lab in 1887 through military mass distribution on both sides of World War II through the postwar pharmaceutical market through biker gang production through Mexican cartel industrialization — and documenting how the same institutional pattern that created mass dependence walked away and handed the population to whatever came next.

This essay is part of The Pharmacological State — a documented history of institutional pharmacology. Each piece stands alone. The history is the argument.

The Soldier's Drug

Amphetamines were issued by governments, prescribed by physicians, manufactured by cartels, and distributed through the same infrastructure that carried crack cocaine. The institution changed at every stage. The population didn't.

The Order

In the spring of 1940, German military command issued 35 million tablets to 3 million Wehrmacht soldiers in the weeks before the invasion of France.

The tablet was called Pervitin. Each one contained 3 milligrams of methamphetamine. Soldiers took three to five tablets per day — sometimes more. Under its influence they fought and marched for ten days without meaningful sleep, covering 22 miles per day through enemy territory. The British press described German paratroopers landing ahead of the advance as heavily drugged, fearless and berserk. Churchill wrote in his memoirs that he was dumbfounded by the speed of the German advance — that he had never expected to face the overrunning of the whole countryside by an irresistible force. General Heinz Guderian, commanding the tank advance, issued an order to his men that captured the operational logic precisely: I demand that you go sleepless for at least three nights if that should be necessary.

The Wehrmacht wasn't trying to build better soldiers. It was trying to remove the biological constraint that made soldiers human — the need for sleep. Pervitin was the solution. The Blitzkrieg was partly an amphetamine delivery system with an army attached.

Veterans who survived it reported a specific fear: that they would never sleep again. That if the drug had taken sleep from them permanently, death would follow. Some of them were right. Psychosis. Heart failure. Suicide. The side effects were severe enough that the army sharply curtailed distribution by late 1940 — not out of concern for the soldiers, but because the withdrawal was destroying unit effectiveness.

The German military then escalated. Late in the war, at the request of Vice-Admiral Hellmuth Heye for a compound that would keep soldiers fighting beyond any period considered normal, a German pharmacologist developed D-IX — a single tablet combining cocaine, methamphetamine, and a morphine-based painkiller simultaneously. Fearless. Tireless. Impervious to pain. All three pharmacological levers pulled at once. It was tested on concentration camp prisoners forced to march with 20-kilogram packs. Mini-submarine crews were issued chewing gum containing 20 milligrams of cocaine and 20 milligrams of methamphetamine for final missions.

The Allies were running the same program. American and British soldiers received Benzedrine — amphetamine, not methamphetamine, a slightly different compound with the same operational logic. RAF Bomber Command issued it to keep pilots awake through long missions. The US military distributed it across multiple theaters. Both sides. Same drug. Different uniforms.

The most extraordinary footnote is the marketing. Pervitin's manufacturer — Temmler Pharmaceutical, based in Berlin — modeled its consumer advertising campaign on Coca-Cola's global marketing strategy. The compound that a morphine-addicted Confederate soldier had put in a soft drink to treat his own dependence became the template for selling military methamphetamine to the German public forty years later. The Blitzkrieg ran on speed. The speed was marketed like Coke. This is institutional pharmacology operating at its most precise — a pharmacological tool adopted for military objectives, distributed at industrial scale, and marketed to a civilian population using the same architecture a previous institution had built around a previous compound.

The Compound

Amphetamine was synthesized in 1887 by Romanian chemist Lazăr Edeleanu in Berlin. He was looking for a simpler way to produce ephedrine — a naturally occurring stimulant derived from a Chinese plant used in traditional medicine for centuries. What he produced instead was a synthetic compound with no natural source and no identified medical application. He set it aside.

Thirty-two years later, in 1919, Japanese chemist Akira Ogata synthesized methamphetamine — a more potent variant — from ephedrine using red phosphorus and iodine. Same story. No immediate application. The compound sat in chemical literature for another decade before anyone understood what to do with it.

What finally unlocked it was not medicine. It was the military.

Otto Ranke — director of the Institute for General and Defense Physiology at Berlin's Academy of Military Medicine — tested Pervitin on ninety college students in the late 1930s and concluded that methamphetamine could help Germany win the war. His reasoning was straightforward. Modern mechanized warfare required soldiers to perform beyond normal human biological limits. Sleep was the enemy of speed. Pervitin eliminated the need for sleep, at least temporarily, and replaced exhaustion with confidence and aggression.

The Temmler pharmaceutical company in Berlin began producing Pervitin in 1938 and marketed it to the German public using Coca-Cola's consumer advertising model as a template — the same marketing architecture a morphine-addicted Confederate soldier had built around cocaine extract forty years earlier. It was briefly available over the counter. Soldiers called the tablets Stuka-Tablets and Hermann-Göring-Pills. By 1940 the Wehrmacht had ordered 35 million of them.

The compound Edeleanu had synthesized as an unremarkable chemical curiosity in 1887 had found its institution. The institution had found its drug.

The War

World War II was the most pharmacologically enhanced military conflict in history. Both sides ran the same program with the same logic — remove the biological constraint of fatigue, extend the operational window, keep the soldiers functional past the point where the human body would otherwise stop.

The Germans had Pervitin. The British and Americans had Benzedrine. The Japanese had Philopon — their own methamphetamine formulation, issued to factory workers and kamikaze pilots alike. The Soviets had their own stimulant protocols. The specific compound differed by theater. The institutional logic was identical everywhere.

For the Allies, Benzedrine was standard issue in aircrews and combat infantry across multiple theaters. RAF Bomber Command distributed it to keep pilots awake through long night missions over Germany. The US military issued it across the Pacific and European theaters. A British military report estimated 72 million Benzedrine tablets were consumed by Allied forces during the war. The amphetamine that American soldiers took in 1944 and the methamphetamine German soldiers took in 1940 were different compounds on the same pharmacological spectrum — stimulants that overrode fatigue, suppressed hunger, and produced aggression and confidence that persisted until the compound wore off.

What happened when it wore off was the part nobody planned for.

Withdrawal from sustained amphetamine use produces the precise opposite of what the drug had delivered — profound exhaustion, depression, cognitive fog, and an inability to feel pleasure that could persist for weeks. Soldiers who had been chemically maintained in a state of heightened alertness and aggression suddenly crashed. The Germans recognized the problem early enough to curtail distribution in 1940 — not out of concern for the soldiers, but because withdrawal was destroying unit cohesion.

The Japanese kamikaze program presents the most extreme version of the institutional logic. Pilots on final missions — one-way missions — were issued methamphetamine as standard protocol. The drug that suppressed the fear response and produced euphoric aggression was operationally ideal for men being asked to fly aircraft into warships. The institution had found the precise pharmacological solution to the problem of asking humans to do something humans would otherwise refuse to do.

When the war ended, three things happened simultaneously. The military supply chains shut down. Stockpiles of amphetamine tablets — particularly in Japan, where pharmaceutical companies had produced enormous quantities for the war effort — flooded civilian markets. And millions of veterans on both sides came home with nervous systems that had been pharmacologically altered by sustained stimulant exposure during the most traumatic period of their lives.

The institution had issued the drug. The institution had ended the war. The institution had no further interest in what the drug had done to the people who took it.

The Domestic Turn

When the war ended the military supply chains shut down. What didn't shut down was the demand.

In Japan the problem was immediate and visible. Pharmaceutical companies had produced enormous quantities of Philopon for the war effort. When the military no longer needed it the stockpiles were released into civilian markets. By the late 1940s methamphetamine addiction had become a national crisis — an estimated 550,000 Japanese were dependent on the compound their government had issued to factory workers and kamikaze pilots as a productivity tool. Japan became the first country to experience a civilian methamphetamine epidemic as a direct consequence of military pharmacology.

In the United States the transition was slower and more institutional. Amphetamine entered the civilian pharmaceutical market under the Benzedrine brand and found a remarkable number of applications. It was prescribed for obesity, depression, narcolepsy, and fatigue. It was available in inhalers sold over the counter — each inhaler containing 250 milligrams of amphetamine, enough for significant abuse. Truck drivers used it to drive through the night. Students used it for examinations. Housewives used it for energy and weight management — physicians prescribed it so routinely that it acquired the informal name Mother's Little Helper.

The creative class found it too. Jack Kerouac wrote the first draft of On the Road on a Benzedrine binge — 120 feet of teletype paper fed through a typewriter in three weeks. The Beat Generation's velocity, its compressed intensity, its refusal of conventional rhythm — partly pharmacological. The same compound the Wehrmacht had used to drive tank columns through the Ardennes was driving literary production in Greenwich Village.

The American military hadn't stopped using it either. Amphetamines were issued in Korea and Vietnam. The institutional relationship between the American military and stimulant pharmacology that had begun with Benzedrine in World War II continued without interruption through three subsequent wars.

The pharmaceutical companies producing amphetamine for the civilian market understood what they had. Prescriptions expanded. Applications multiplied. The compound synthesized as a chemical curiosity in 1887 and weaponized by the Wehrmacht in 1940 was by 1970 one of the most widely prescribed medications in American history.

Then the regulatory environment shifted. The Controlled Substances Act of 1970 placed amphetamines under Schedule II control. Prescriptions became harder to obtain. The pharmaceutical supply contracted — and the demand it had built didn't contract with it. This is the defining mechanism of retail pharmacology: when the institutional supply chain closes, the market finds another source.

The market found one.

The Cartel Lab

When the pharmaceutical supply contracted, the biker gangs filled the gap.

Hell's Angels and affiliated outlaw motorcycle organizations had been producing methamphetamine domestically since the 1970s — small labs, regional distribution, a market that stayed largely contained within specific subcultures. They controlled domestic meth production for nearly two decades. The product was crude by pharmaceutical standards. The distribution was disorganized. The market was real but limited.

Then the Mexican cartels looked at it and saw something different.

The Colima Cartel — a relatively small Mexican trafficking organization that had been working as a cocaine courier for the Colombian cartels — made a strategic decision in the early 1990s that would reshape the American drug market. They identified methamphetamine as a product with structural advantages no agricultural drug could match. No crop. No growing season. No geography. No dependence on Colombian suppliers or Bolivian coca farmers. Precursor chemicals sourced from Asia — primarily ephedrine from Chinese and Indian pharmaceutical companies — synthesized in Mexican labs into finished product. The entire supply chain ran on chemistry and logistics, not agriculture.

They built large-scale superlabs in Mexico and California and displaced the biker gangs within a decade. By 2001 DEA reporting confirmed that Mexican drug organizations now dominated the American methamphetamine market — a market that had previously been controlled entirely by domestic American producers.

The cartel had taken its first fully synthetic product to scale. No poppy fields. No coca cultivation. Just precursor chemicals and labs. The profit margins were dramatically better than cocaine. The supply chain was more resilient. The product was more addictive.

The US government responded with the Combat Methamphetamine Epidemic Act of 2005 — restricting domestic pseudoephedrine sales and requiring identification at point of sale. The domestic small-lab meth economy effectively collapsed. Mexican cartel production was unaffected. The cartels simply sourced precursor chemicals internationally from China and continued supplying the American market from across the border. Supply restriction domestically had transferred market control to the cartels more completely than any previous policy had managed.

The lesson was already visible in the cocaine story — interdiction of precursor chemicals doesn't eliminate supply, it consolidates market control in the hands of the most sophisticated producer.

The proof of concept was now complete. A fully synthetic drug — no agricultural supply chain, no geographic constraint, precursor chemicals sourced from compliant Asian suppliers — could be manufactured at industrial scale, moved through existing distribution infrastructure, and delivered to American retail markets with profit margins that dwarfed agricultural drugs.

Fentanyl was the logical next step. The cartels took it.

The Inheritance

The arc from a Berlin chemistry lab in 1887 to a Mexican cartel superlab in 2024 runs through one continuous institutional relay.

A Romanian chemist synthesized amphetamine as an unremarkable chemical curiosity. A Japanese chemist synthesized methamphetamine as a more potent variant. Neither found an application. Then the military found them both — and issued them to soldiers on both sides of the most destructive war in history. Soldiers came home with altered nervous systems, no treatment framework, and no institutional acknowledgment of what had been done to them. The pharmaceutical industry absorbed the demand through the postwar prescription market. The regulatory apparatus eventually contracted the supply. The biker gangs filled the gap. The Mexican cartels displaced the biker gangs and scaled the product industrially. Chinese precursor chemical suppliers — some with documented state ties, operating with CCP knowledge and protection — supply the raw materials. Fentanyl is the logical endpoint of the same synthetic model methamphetamine proved.

The population on the receiving end of this relay was being prepared at every stage.

The military created stimulant-sensitized veterans. The pharmaceutical industry normalized stimulant use as a solution to productivity, mood, and weight management across the civilian population. The compressed attention economy — social media, ultra-processed food, the entire architecture of interval compression built into modern consumer life — further lowered the threshold. The person who arrives at methamphetamine or fentanyl in 2024 is not arriving with a naive nervous system. They are arriving with a nervous system that has been shaped by decades of institutional and commercial pharmacological pressure — military, pharmaceutical, criminal, and behavioral — all operating on the same biological infrastructure that interval compression has been tightening for generations. The population the relay created is the kindled market — already prepared, already primed, threshold already lowered before the compound arrives.

The compound the Wehrmacht called Pervitin and the troops called Hermann-Göring-Pills is now synthesized in industrial quantities in Sinaloa and Jalisco and distributed through the same networks that carried crack cocaine in the 1980s. The marketing that Temmler Pharmaceutical modeled on Coca-Cola in 1938 has been replaced by the retail pharmacology ecosystem — energy drinks, pre-workout supplements, ADHD medications, and the gas station stimulant shelf that sits one product category away from the kratom extract display.

The institution issued the drug. The institution walked away. The market inherited the demand. The population absorbed the consequences.

It has worked this way every time.